Sudarshan Pharma Industries (543828) Q1 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved and reviewed by the Board and auditors, with the first-time adoption of Ind AS from April 1, 2024.

• The company operates in the specialty chemicals sector, with no reportable segments under Ind AS 108.

Financial highlights

• Standalone revenue from operations for Q1 FY26 was ₹14,231.10 lakhs, up from ₹14,372.56 lakhs in Q1 FY25 and down from ₹16,156.81 lakhs in Q4 FY25.

• Standalone net profit for Q1 FY26 was ₹373.28 lakhs, compared to a net loss of ₹117.95 lakhs in Q1 FY25 and a profit of ₹702.68 lakhs in Q4 FY25.

• Consolidated revenue for Q1 FY26 was ₹14,526.16 lakhs, up from ₹9,920.02 lakhs in Q1 FY25 and down from ₹16,159.39 lakhs in Q4 FY25.

• Consolidated net profit for Q1 FY26 was ₹395.85 lakhs, compared to a net loss of ₹120.74 lakhs in Q1 FY25 and a profit of ₹741.27 lakhs in Q4 FY25.

• Basic and diluted EPS for Q1 FY26 stood at ₹0.15 (standalone) and ₹0.16 (consolidated).

Outlook and guidance

• The company continues to focus on specialty chemicals and pharmaceutical manufacturing, with recent acquisitions aimed at expanding global reach.